Peripheral cholinergic disturbances in Alzheimer's disease

被引:25
|
作者
Rakonczay, Z [1 ]
Horváth, Z
Juhász, A
Kálmán, J
机构
[1] Univ Szeged, Alzheimers Dis Res Ctr, Dept Oral Biol, Szeged, Hungary
[2] Univ Szeged, Fac Med, Dept Psychiat, H-6720 Szeged, Hungary
关键词
Alzheimer's disease; acetylcholinesterase; butyrylcholinesterase; molecular forms; apolipoprotein E; butyrylcholinesterase K variant;
D O I
10.1016/j.cbi.2005.10.034
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The most pronounced neurochemical abnormality in Alzheimer's disease (AD) is cholinergic dysfunction in the central nervous system. Peripheral tissues may also be affected, however, including blood. The present study undertook to determine the activity of acetylcholinesterase (AChE) and its molecular forms in erythrocytes, lymphocytes and platelets of normal elderly subjects and probable AD cases. These samples contained dimeric globular (G2), tetrameric globular (G4) and asymmetric (A12) AChE forms, but no globular monomeric (G1) enzyme. In both lymphocytes and platelets, the major AChE molecular form was G2 (approximately 80%), with G4 and A12 forms accounting for nearly equal portions of the remainder. Total AChE activities and measured sedimentation coefficients were similar in the control and AD samples (from patients with mild and moderately severe cognitive deficiency). However, the groups differed significantly in the proportion of certain AChE molecular forms. Thus, as compared with controls, the amount of A 12 AChE in the AD samples was increased 148 and 161% in lymphocytes and platelets, respectively. Genotyping for apolipoprotein E (ApoE) and the butyrylcholinesterase K (BCHE-K) variant, carried out using the polymerase chain reaction, showed that AD patients carried the ApoE4 allele at a significantly higher frequency than the controls. On the other hand there were no significant group differences in the occurrence of the BCHE-K variant and no synergism between ApoE alleles and the BCHE-K variant in our Hungarian AD population. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:233 / 238
页数:6
相关论文
共 50 条
  • [41] Treatment of Alzheimer's disease:: an evaluation of the cholinergic approach
    Lemière, J
    van Gool, D
    Dom, R
    ACTA NEUROLOGICA BELGICA, 1999, 99 (02) : 96 - 106
  • [42] The cholinergic hypothesis of Alzheimer's disease: a review of progress
    Francis, PT
    Palmer, AM
    Snape, M
    Wilcock, GK
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (02): : 137 - 147
  • [43] The EEG as indicator of the cholinergic deficit in Alzheimer's disease
    Adler, G
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2000, 68 (08) : 352 - 356
  • [44] Cholinergic neuropathology in a mouse model of Alzheimer's disease
    German, DC
    Yazdani, U
    Speciale, SG
    Pasbakish, P
    Games, D
    Liang, CL
    JOURNAL OF COMPARATIVE NEUROLOGY, 2003, 462 (04) : 371 - 381
  • [45] Cholinergic deficiency in Alzheimer's disease - Pathogenic model
    Schneider, LS
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 1998, 6 (02): : S49 - S55
  • [46] PET studies and cholinergic therapy in Alzheimer's disease
    Nordberg, A
    REVUE NEUROLOGIQUE, 1999, 155 : 4S53 - 4S63
  • [47] Cognitive cholinergic therapy of anomia in Alzheimer's disease
    Fuller, RH
    Kendall, DL
    Nadeau, SE
    Spevack, AA
    Heilman, KM
    Gonzalez-Rothi, LJ
    NEUROLOGY, 2001, 56 (08) : A57 - A57
  • [48] The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
    Hampel, Harald
    Mesulam, M. -Marsel
    Cuello, A. Claudio
    Farlow, Martin R.
    Giacobini, Ezio
    Grossberg, George T.
    Khachaturian, Ara S.
    Vergallo, Andrea
    Cavedo, Enrica
    Snyder, Peter J.
    Khachaturian, Zaven S.
    BRAIN, 2018, 141 : 1917 - 1933
  • [49] Galantamine:: a novel cholinergic agent for Alzheimer's disease
    Olazarán, J
    García, G
    NEUROLOGIA, 2002, 17 (08): : 429 - 436
  • [50] Neurotrophins and Alzheimer's disease: Beyond the cholinergic neurons
    Knusel, B
    Gao, H
    LIFE SCIENCES, 1996, 58 (22) : 2019 - 2027